[HTML][HTML] Functionalized liposomes for targeted breast cancer drug delivery

J Nel, K Elkhoury, É Velot, A Bianchi, S Acherar… - Bioactive materials, 2023 - Elsevier
Despite the exceptional progress in breast cancer pathogenesis, prognosis, diagnosis, and
treatment strategies, it remains a prominent cause of female mortality worldwide …

[HTML][HTML] The past, present, and future of breast cancer models for nanomedicine development

P Boix-Montesinos, PM Soriano-Teruel… - Advanced drug delivery …, 2021 - Elsevier
Even given recent advances in nanomedicine development of breast cancer treatment in
recent years and promising results in pre-clinical models, cancer nanomedicines often fail at …

[HTML][HTML] A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer

H Kumar, NV Gupta, R Jain… - Journal of Advanced …, 2023 - Elsevier
Background Triple-negative breast cancer (TNBC) is a heterogeneous, aggressive
phenotype of breast cancer with associated chemoresistance. The development of chemo-or …

Lipid-based nanoparticles as a pivotal delivery approach in triple negative breast cancer (TNBC) therapy

A Chaudhuri, DN Kumar, RA Shaik, BG Eid… - International journal of …, 2022 - mdpi.com
Triple-negative breast cancer is considered the most aggressive type of breast cancer
among women and the lack of expressed receptors has made treatment options …

Erythrocyte leveraged chemotherapy (ELeCt): Nanoparticle assembly on erythrocyte surface to combat lung metastasis

Z Zhao, A Ukidve, Y Gao, J Kim, S Mitragotri - Science Advances, 2019 - science.org
Despite being the mainstay of cancer treatment, chemotherapy has shown limited efficacy
for the treatment of lung metastasis due to ineffective targeting and poor tumor accumulation …

Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases

Z Zhao, A Ukidve, V Krishnan, A Fehnel… - Nature Biomedical …, 2021 - nature.com
Eliciting immune responses against primary tumours is hampered by their
immunosuppressive microenvironment and by the greater inaccessibility of deeper …

Synthetic cells in biomedical applications

W Sato, T Zajkowski, F Moser… - Wiley Interdisciplinary …, 2022 - Wiley Online Library
Synthetic cells are engineered vesicles that can mimic one or more salient features of life.
These features include directed localization, sense‐and‐respond behavior, gene …

Dual affinity to RBCs and target cells (DART) enhances both organ-and cell type-targeting of intravascular nanocarriers

LT Ferguson, ED Hood, T Shuvaeva, VV Shuvaev… - ACS …, 2022 - ACS Publications
A long-standing goal of nanomedicine is to improve a drug's benefit by loading it into a
nanocarrier that homes solely to a specific target cell and organ. Unfortunately, nanocarriers …

Current understandings and clinical translation of nanomedicines for breast cancer therapy

Y Jiang, Z Jiang, M Wang, L Ma - Advanced drug delivery reviews, 2022 - Elsevier
Breast cancer is one of the most frequently diagnosed cancers that is threatening women's
life. Current clinical treatment regimens for breast cancer often involve neoadjuvant and …

A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo

P Guo, J Huang, B Zhu, AC Huang, L Jiang, J Fang… - Science …, 2023 - science.org
Triple-negative breast cancer (TNBC) remains the most lethal form of breast cancer, and
effective targeted therapeutics are in urgent need to improve the poor prognosis of TNBC …